BioWorld Asia

Feb. 4, 2004

Cyclacel's Fourth Round Gets $39M For Cell Cycle Inhibitors

LONDON - Cyclacel Ltd. raised £21.3 million (US$39 million) in an oversubscribed fourth round of private funding, bringing its total private equity raised to date to $123 million. (BioWorld International) Read More

Acambis Moving R&D Core To U.S.,Cutting Work Force By 40

Predatory Bacterium Could Hold Key To Antibiotic Treasure Trove

With GLP-2 In Osteoporosis Focus, Sanos Raises $10M

PharmaMar Cutting Staff To Conserve Cash For Yondelis

ExonHit Raises Additional EUR8.3M; Now Has Cash To Last Into 2006

Another European Request For Lifting GMO Moratorium

Dissent With Partner Spurs Cutbacks At Micromet AG

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 25, 2026.

Have brain-computer interfaces finally arrived?

BioWorld

More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 23, 2026

2026 marks critical turning point for BCI technology

BioWorld

Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...

Brain-computer interfaces are here but long road ahead

BioWorld

The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...